ALGEN.PA

Genoway

ALGEN.PA, France

genOway Société anonyme, a biotechnology company, engages in the development and commercialization of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive and inducible KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was incorporated in 1999 and is based in Lyon, France.

https://www.genoway.com

Stock Price

€0.00

0%

increase compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
ALGEN.PA
stock
ALGEN.PA

Algen Biotechnologies Announces Multi-Target Partnership with AstraZeneca PharmExec.com

Read more →
ALGEN.PA
stock
ALGEN.PA

AstraZeneca signs $555 million gene-editing deal with Algen - report Investing.com

Read more →

Showing 2 of 4

Finn Analysis

(Last Updated 2025-06-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very High

14.72

Low 50

High 10

Price to Book Ratio (P/B)

-

Very Low

1.39

Low 1

High 3

Return on Equity (ROE)

-

Very Low

0.78 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

0.37 %

Low 2%

High 10%

Debt to Equity

-

Very Low

1.11

Low 1

High 0.3

Investors

* Institutions hold a combined 0.00% of the total shares of Genoway

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

EPS Estimate

Latest Release

Date

2025-06-30

EPS Actual

0

EPS Estimate

0

EPS Difference

0

Surprise Percent

0%

Investing Fit Scorecard

(Last Updated 2025-06-30)

Deep Value
Potential Value Candidate(4.5)
Defensive
Moderately Defensive(6)
Dividend
Weak Dividend Profile(1.5)
Economic Moat
Some Competitive Advantage(5.3)
GARP
Not Attractive for GARP(1.5)
Growth
Weak Growth Prospect(1.5)
Momentum
Strong Momentum(7)
Net Net
Not Undervalued (Net-Net)(1)
Quality
Low Quality Business(2.5)
Value
Fair Value(6)

Income Statement

(Last Updated 2025-06-30)

Revenue

€ 0

Cost Of Revenue

€ 0

Gross Profit

€ 0

Operating Expenses

€ 0

Operating Income

€ 0

Interest Expense

€ 0

Pretax Income

€ 0

Net Income

€ 0

Income Tax Expense

€ 0

EBITDA

€ 0

Total Other Income Expense Net

€ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-06-30)

Cash

0

Short Term Investments

0

Receivables

0

Inventories

0

Total Current Assets

0

Property Plant Equipment

0

Total Assets

0

Payables

0

Short Term Debt

0

Long Term Debt

0

Total Liabilities

0

Equity

0

Trend

Cash Flow

(Last Updated 2025-06-30)

Net Income

0

Depreciation

0

Change In Working Capital

0

Cash From Operations

0

Capital Expenditures

0

Cash From Investing

0

Cash From Financing

0

Net Change In Cash

0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.